---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-026929"
form_type: "8-K"
ticker: "HSCS"
cik: "0001468492"
company_name: "HeartSciences Inc."
filed_at: "2022-12-22T23:59:59+00:00"
generated_at: "2026-06-20T23:59:55.977363+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# HeartSciences targets FDA De Novo resubmission around fiscal year end; cash $3.1M

## Summary
- Patient enrollment for MyoVista pivotal study near completion; resubmission target around April 2023 fiscal year-end.
- Cash and cash equivalents $3.1M as of Oct 31, 2022; sufficient through FDA resubmission.
- No meaningful revenue in Q2 fiscal 2023 as development-stage company.
- Entered multi-year collaboration with Rutgers University for AI algorithm development.
- AMA issued new Category III CPT codes covering AI assistive ECG risk assessments for cardiac dysfunction.

## SEC filing metadata
- accession: 0000950170-22-026929
- form_type: 8-K
- ticker: HSCS
- cik: 0001468492
- company_name: HeartSciences Inc.
- filed_at: 2022-12-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1468492/000095017022026929/0000950170-22-026929-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1468492/000095017022026929/hscs-20221222.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-026929
- JSON: https://secwatch.observer/filing/0000950170-22-026929.json
- Plain text: https://secwatch.observer/filing/0000950170-22-026929.txt

## Key facts
- Earnings Releases
  HeartSciences Inc. reported financial results for the fiscal 2023 second quarter ended October 31, 2022.
  - Period: the fiscal 2023 second quarter ended October 31, 2022
  - Result: reported results
  source text: On December 16, 2022, Heart Test Laboratories, Inc. (the "Company") issued a press release providing information regarding the Company's financial and operating results for the quarter ended October 31, 2022, and other business updates.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1468492/000095017022026929/0000950170-22-026929-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.